Publications by authors named "Andrew Matlob"
Ann Pharmacother
July 2024
Article Synopsis
- - The text reviews the effectiveness and safety of intravenous sulbactam-durlobactam (SUL-DUR) for treating infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB), highlighting two clinical trials comparing SUL-DUR to other treatments.
- - A phase II trial showed a treatment success rate of 76.6% for SUL-DUR, while a phase III trial found it was noninferior to colistin regarding 28-day mortality rates, suggesting SUL-DUR is a competitive option.
- - The authors note the limited treatment options for CRAB infections and recommend further studies to clarify SUL-DUR's efficacy alone or in combination with other drugs, particularly its
